Advanced / metastatic solid tumors
Conditions
Interventions
Participants will receive raludotatug deruxtecan (R-DXd) administered intravenously every 3 weeks (Q3W).
Sponsors
Inoguchi Akihiro
Merck Sharp & Dohme LLC
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria Participants must meet all of the following criteriato be eligible for enrollment into the trial: 1. Sign and date the ICF prior to the start of any trial-specific qualification procedures. 2. Adults >=18 years of age on the day of signing the ICF. Follow local regulatory requirements if the legal age of consent for trial participation is >18 years old. 3. Participants must have at least 1 lesion, not reviously irradiated, amenable to biopsy, and must consent to provide a pre-treatment biopsy from a primary and/or metastatic lesion. 4. Has at least 1 measurable lesion evaluated by computed tomography (CT) or magnetic resonanceimaging (MRI) according to RECIST version 1.1 perinvestigator assessment. 5. Participants must have progressed radiologically on or after their most recent line of systemic therapy. 6. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. 7. Required baseline local laboratory data (within14 days prior to the first administration of trial intervention) as specified in the protocol. 8. Additional inclusion criteria for endometrial cancer cohorta. Pathologically or cytologically documented endometrial cancer (carcinoma of any histological subtype or carcinosarcoma), irrespective of MSI or mismatch repair status.b. Documented disease progression after having received >=1 line of therapy (no more than 3), including PBC-containing systemic treatment and an anti-PD-1 therapy containing regimen (combined or sequential) in the advanced/metastatic setting. 9. Additional inclusion criteria for cervical cancer cohorta. Pathologically or cytologically documented recurrent or persistent squamous, adenosquamous, or adenocarcinoma of the uterine cervix.b. Disease progression after having received >=1 prior line of therapy that includes systemic therapy in the advanced or metastatic setting. 10. Additional inclusion criterion for non-HGSOC cohorta. Pathologically or cytologically documented unresectable or metastatic CCOC, low grade endometrioid, low-grade serous, or mucinous OVC that waspreviously treated with at least 1 prior line of therapy. 11. Additional inclusion criteria for urothelial cancer cohort a. Pathologically or cytologically documented unresectable or metastatic urothelial carcinoma of thebladder, renal pelvis, ureter, or urethra. Histological variants are allowed if urothelial histology is predominant. b. Relapsed or progressed after treatment with >=1prior line of therapy (maximum of 3) that containsanti-PD-(L)1 therapy in the perioperative or metastatic setting. At least 1 line of therapy must also contain one of the following treatment modalities: chemotherapy or EV. Prior fibroblast growth factorreceptor-inhibitor treatment for those who are eligible is allowed. *Required treatments can be given in combination or sequentially. *Prior cisplatin-based therapy or PD-(L)1 therapygiven for the treatment of muscle invasive urothelial carcinoma is counted as 1 line of therapy. *The same regimen administered twice in different disease settings will be counted as 1 line of prior therapy. *A minimum of 20 participants in the 2L settingwho have previously received EV and pembrolizumab in combination will be enrolled. 12. ccRCC cohorta. Pathologically or cytologically documented unresectable or metastatic ccRCC that was previously treated with no more than 3 prior systemic regimens for locally advanced or metastatic RCC, including both a PD-(L)1 checkpoint inhibitor and a VEGF-TKI
Exclusion criteria
Exclusion criteria: Participants who meet any of the following criteria will be disqualified from entering the trial: 1. Inadequate washout period before C1D1 as specified in the protocol. 2. Clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated or symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms. 3. Participants with current bowel involvement/obstruction (including subocclusive disease) related to underlying disease, a history of abdominal fistula, GI perforation, or intraabdominal abscess, or evidence of rectosigmoid involvement by pelvic examination, bowel involvement on CT, or clinical symptoms of bowel obstruction interfering with nutrition. 4. Any of the following within the past 6 months prior to enrollment: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event. 5. Uncontrolled or significant cardiovascular disease as specified in the protocol. 6. Has a history of (noninfectious) ILD/pneumonitis that required corticosteroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. 7. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder and any autoimmune, connective tissue, or inflammatory disorder with potential pulmonary involvement or prior pneumonectomy. 8. Chronic steroid treatment (>10 mg/day) with exceptions as noted in the protocol. 9. History of other active malignancy within 3 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death (eg, 5-year OS rate >90%) and treated with expected curative outcome. 10. Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE Version 5.0, Grade <=1 or baseline. 11. Prior exposure to other CDH6-targeted agents or an ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor (eg, trastuzumab deruxtecan, datopotamab deruxtecan). 12. History of hypersensitivity to any excipients in R-DXd or any known contraindication (included in the approved local labels) to treatment with, including hypersensitivity to, the trial intervention. 13. Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection. Participants with localized fungal infections of skin or nails are eligible. 14. Has active or uncontrolled HIV infection. 15. Has any evidence of severe or uncontrolled systemic diseases (including active bleeding diatheses or active infection, substance abuse) or other factors that, in the investigator's opinion, makes it undesirable for the participant to participate in the trial or which would jeopardize compliance with the protocol. 16. Has active or uncontrolled hepatitis B virus infection. 17. Has active or uncontrolled hepatitis C virus infection. 18. Female who is pregnant or breastfeeding or intends to become pregnant during the trial. 19. Men who plan to father a child while in the trial and for at least 4 months after the last administration of trial intervention. 20. Psychological, social, familial, or geographical factors that would prevent regular follow-up. 21. Prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Objective Response Rate (ORR) as assessed by the investigator (all cohorts except ccRCC) ORR is defined as the proportion of participants with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.1 criteria. - Disease Control Rate (DCR) as assessed by the investigator (ccRCC cohort only) DCR is defined as proportion of participants who achieved a BOR of confirmed CR, confirmed PR, or stable disease (maintained for >=5 weeks) according to RECIST version 1.1. - Incidence of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs) (All Cohorts) | — |
Secondary
| Measure | Time frame |
|---|---|
| - Progression-free Survival (PFS) as Assessed by the Investigator Progression-free survival (PFS) is defined as the time interval from the start date of trial intervention to the date of radiographic disease progression according to RECIST version 1.1 criteria or death due to any cause, whichever comes first. - Duration of Response (DoR) as Assessed by the Investigator Duration of response (DoR) is defined as the time from the date of the first documentation of objective response (CR or PR) that is subsequently confirmed to the date of the first documentation of radiographic disease progression according to RECIST version 1.1 criteria or death due to any cause, whichever occurs first. - Time to Response (TTR) as Assessed by the Investigator Time to response (TTR) is defined as the time from the start date of trial intervention to the date of the first documentation of response (CR or PR) that is subsequently confirmed. TTR will be calculated for confirmed responders only. - Objective Response Rate as Assessed by the Investigator (ccRCC Cohort Only) Objective response rate (ORR) is defined as the proportion of participants with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST version 1.1 criteria. - Disease Control Rate (DCR) as Assessed by the Investigator (All Cohorts Except ccRCC Cohort) Disease control rate (DCR) is defined as proportion of participants who achieved a BOR of confirmed CR, confirmed PR, or stable disease (maintained for >=5 weeks) according to RECIST version 1.1. - Pharmacokinetic Parameters (Cmax, Tmax, AUC, Cmin) -Incidence of participants who are Anti-Drug Antibody (ADA)-Positive at any time and who have a treatment-emergent ADA | — |
Countries
Belgium, China, Denmark, France, Italy, Japan, Korea, Spain, United States
Contacts
Public ContactContact for Clinical Trial Information
Daiichi Sankyo Co., Ltd.
Outcome results
None listed